Brainsafe II

Back to Projects

The BrainSafe II project aims to develop innovative technology for non-invasive fast-and-easy, accurate and precise absolute intracranial pressure (aICP) diagnostics. The timely application of the device in the diagnosis of TBI patients will save approximately 9.400 lives, reduce the number of permanently disabled citizens by 30.000 and increase the survival rates and lifespan for an additional 136.000 patients with TBI within the EU annually. The innovative aICP measurement device will completely eliminate all the risks associated with invasive methods of ICP diagnostics.

 

 

 

 

The technical concept of the BrainSafe project relies on TCD blood flow parameter measurements at two depths within the Ophthalmic Artery (OA).

This concept is currently protected by several patents owned by BrainSafe II project initiator and coordinator - Vittamed. Initial proof of concept studies including preliminary clinical studies and anatomic studies of the eye artery have been carried out with success. These studies have formed the basis for the objectives of the BrainSafe II project.

The first reason of death of population under 45 years in developed countries is head trauma. Each year, over 3 million patients in Europe and North America have a traumatic brain injury (TBI) which places them at risk of brain damage and death from swelling of brain tissue. Monitoring intracranial pressure is vital to detect and control this swelling.

Currently ICP can only be measured using an invasive surgical procedure, in which a clinician drills a hole in the patient’s skull and inserts a probe into the brain. The cost, complexity and risks involved mean that ICP is measured only in the most critically ill patients and not in the millions of patients who are at mild to moderate risk. The procedure requires specialized neurosurgeon to place the catheter inside the patient’s skull that exposes the patients to the risk of infection, bleeding, and leak of fluids or loss of other body tissue, pain, and hyperthermia as well as risks related to anaesthetics. Relative to these risks and complexity of the procedure, only 20% of all TBI patients get access to the diagnostics of ICP, leaving out 1,280,000 TBI patients without proper examination of their brain injuries in Europe yearly. The lack of early diagnosis of increased ICP causes 100,000 new long-term disabilities and 400,000 deaths each year for these patients. Early diagnosis of mild and moderate TBI also requires non-invasive absolute ICP value measurement.

Project Partners:

Kaunas University of Technology

Artec Design

Medelkom

Eesti Innovatsiooni Instituut

Microplast AS

Singer Instruments & control LTD

LTD Vittamed

 

For more information on the BrainSafe project, please visit the project web site.

 

Back to Projects

Tags: